Shelley Welch
YOU?
Author Swipe
View article: CTIM-09. PHASE II RUN-IN STUDY OF DARATUMUMAB IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA
CTIM-09. PHASE II RUN-IN STUDY OF DARATUMUMAB IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA Open
BACKGROUND Daratumumab, a CD38-targeted monoclonal antibody, has shown preclinical activity in glioblastoma (GBM). Given the expression of CD38 on GBM cells, daratumumab’s mechanisms, potentially mirroring multiple myeloma, may include dir…
View article: Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort
Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort Open
In this cross-sectional study, anti-RBD IgG levels decreased after vaccination or infection. Higher antibody responses were found in individuals who received a third (booster) vaccination. Although lower antibody levels were associated wit…
View article: Serological survey of SARS-CoV-2 incidence conducted at a rural West Virginia hospital
Serological survey of SARS-CoV-2 incidence conducted at a rural West Virginia hospital Open
The SARS-CoV-2 pandemic has affected all types of global communities. Differences in urban and rural environments have led to varying levels of transmission within these subsets of the population. To fully understand the prevalence and imp…